Dolby Laboratories, Inc. (DLB) Stock Price Today
Aura AI Summary
Key Stats
- $4.71BMarket Cap
- -Volume
- IndustrialsSector
- $76.7952W High
- $49.3152W Low
- -Typical Hold Time
- $4.17BEnterprise Value
- 2.83%Div Yield
- -Trading Activity
Track Dolby Laboratories, Inc. (DLB) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Dolby Laboratories, Inc. has traded between a low of $49.31 and a high of $76.79, highlighting its annual price range. Buy and sell Dolby Laboratories, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Most Recent News
Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...

Alamar Biosciences launches national study analyzing 21,000 plasma samples to advance Alzheimer's biomarkers.
Alamar Biosciences has partnered with top U.S. research universities to start a nationwide proteomics project using its NULISAseq™ Neuro 220 panel. The study will analyze about 21,000 plasma samples from 10,000 Alzheimer's and related dementia partic...

Alamar Biosciences launches national study using blood tests to advance Alzheimer's biomarker research.
Alamar Biosciences has partnered with leading U.S. universities to launch a nationwide proteomics study analyzing around 21,000 plasma samples from 10,000 Alzheimer's and related dementia patients. Using its NULISAseq™ Neuro 220 test kit, the project...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.